Advertisement

Optic Pathway Gliomas

  • Arnold C. Paulino
Chapter

Abstract

Although comprising only 1% of all brain tumors, optic pathway glioma (OPG) is the most common optic pathway tumor. While many cases are found in young children, 20–40% are found in patients ≥15 years. Neurofibromatosis type 1 (NF1) is a well-known risk factor, with about 15–20% with NF1 developing OPG which tend to be more indolent than the non-NF1 OPG. Most are pilocytic astrocytomas, but other types of low-grade and malignant gliomas have been reported. The role of surgery is to obtain tissue diagnosis or resection in the patient with glioma confined just to the optic nerve and complete visual loss. Chemotherapy consisting of carboplatin and vincristine is a popular treatment approach to delay radiotherapy (RT) in children <10 years and preserve neurocognitive function. In NF1 patients, RT is often avoided because of the higher chance of developing vascular and neoplastic events. RT is the mainstay of treatment for non-NF1 patients who are ≥10 years. The 10-year overall survival and progression-free survival rates range from 80% to 95% and 70% to 85%, respectively, with RT. In addition, stabilization and improvement in vision have been observed in more than 70% of patients receiving RT.

Keywords

Optic pathway glioma Hypothalamic chiasmatic glioma Radiotherapy Surgery Chemotherapy Observation Neurofibromatosis type 1 

References

  1. 1.
    Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994;38(5):427–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Binning MJ, Liu JK, Kestle JR, et al. Optic pathway gliomas: a review. Neurosurg Focus. 2007;23(5):E2.PubMedCrossRefGoogle Scholar
  3. 3.
    Kornreich L, Blaser S, Schwarz M, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol. 2001;22(10):1963–9.PubMedGoogle Scholar
  4. 4.
    King A, Listernick R, Charrow J, et al. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A. 2003;122a(2):95–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41(2):143–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Prada CE, Hufnagel RB, Hummel TR, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015;167(4):851–6.e1.PubMedCrossRefGoogle Scholar
  7. 7.
    Nicolin G, Parkin P, Mabbott D, et al. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer. 2009;53(7):1231–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Khafaga Y, Hassounah M, Kandil A, et al. Optic gliomas: a retrospective analysis of 50 cases. Int J Radiat Oncol Biol Phys. 2003;56(3):807–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Hartel PH, Rosen C, Larzo C, et al. Malignant optic nerve glioma (glioblastoma multiforme): a case report and literature review. W V Med J. 2006;102(4):29–31.PubMedGoogle Scholar
  10. 10.
    Bommakanti K, Panigrahi M, Yarlagadda R, et al. Optic chiasmatic-hypothalamic gliomas: is tissue diagnosis essential? Neurol India. 2010;58(6):833–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013;2(2):143–59.PubMedCrossRefGoogle Scholar
  12. 12.
    Parsa CF, Hoyt CS, Lesser RL, et al. Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging. Arch Ophthalmol. 2001;119(4):516–29.PubMedCrossRefGoogle Scholar
  13. 13.
    Addy DP, Hudson FP. Diencephalic syndrome of infantile emaciation. Analysis of literature and report of further 3 cases. Arch Dis Child. 1972;47(253):338–43.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Goodden J, Pizer B, Pettorini B, et al. The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr. 2014;13(1):1–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoffman HJ, Soloniuk DS, Humphreys RP, et al. Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. Neurosurgery. 1993;33(6):964–71.PubMedGoogle Scholar
  16. 16.
    Steinbok P, Hentschel S, Almqvist P, et al. Management of optic chiasmatic/hypothalamic astrocytomas in children. Can J Neurol Sci. 2002;29(2):132–8.PubMedGoogle Scholar
  17. 17.
    Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg. 1990;73(5):661–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Merchant TE, Conklin HM, Wu S, et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27(22):3691–7.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Mahoney DH Jr, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol. 2000;2(4):213–20.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Gnekow AK, Kortmann RD, Pietsch T, et al. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy — report from the multicenter treatment study for children and adolescents with a low grade glioma — HIT-LGG 1996 — of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr. 2004;216(6):331–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Chong AL, Pole JD, Scheinemann K, et al. Optic pathway gliomas in adolescence—time to challenge treatment choices? Neuro Oncol. 2013;15(3):391–400.PubMedCrossRefGoogle Scholar
  23. 23.
    Jahraus CD, Tarbell NJ. Optic pathway gliomas. Pediatr Blood Cancer. 2006;46(5):586–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Shofty B, Mauda-Havakuk M, Weizman L, et al. The effect of chemotherapy on optic pathway gliomas and their sub-components: a volumetric MR analysis study. Pediatr Blood Cancer. 2015;62(8):1353–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Stieber VW. Radiation therapy for visual pathway tumors. J Neuroophthalmol. 2008;28(3):222–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Merchant TE, Kun LE, Wu S, et al. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2009;27(22):3598–604.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Paulino AC, Mazloom A, Terashima K, et al. Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013;119(14):2654–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Marcus KJ, Goumnerova L, Billett AL, et al. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005;61(2):374–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys. 2011;79(3):650–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Desai SS, Paulino AC, Mai WY, et al. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys. 2006;65(4):1222–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120(1):126–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999;45(5):1117–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Tao ML, Barnes PD, Billett AL, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys. 1997;39(3):579–87.PubMedCrossRefGoogle Scholar
  35. 35.
    Horwich A, Bloom HJ. Optic gliomas: radiation therapy and prognosis. Int J Radiat Oncol Biol Phys. 1985;11(6):1067–79.PubMedCrossRefGoogle Scholar
  36. 36.
    Erkal HS, Serin M, Cakmak A. Management of optic pathway and chiasmatic-hypothalamic gliomas in children with radiation therapy. Radiother Oncol. 1997;45(1):11–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Grabenbauer GG, Schuchardt U, Buchfelder M, et al. Radiation therapy of optico-hypothalamic gliomas (OHG)—radiographic response, vision and late toxicity. Radiother Oncol. 2000;54(3):239–45.PubMedCrossRefGoogle Scholar
  38. 38.
    Combs SE, Schulz-Ertner D, Moschos D, et al. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005;62(3):814–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Lacaze E, Kieffer V, Streri A, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer. 2003;89(11):2038–44.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Awdeh RM, Kiehna EN, Drewry RD, et al. Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):46–51.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Campagna M, Opocher E, Viscardi E, et al. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer. 2010;55(6):1083–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010;46(12):2253–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyMD Anderson Cancer CenterHoustonUSA

Personalised recommendations